Leukemia-drug competitors of Infinity Pharmaceuticals Inc., The Wall Street Journal reported, had strong if incremental releases of scientific data about their products Wednesday. But JPMorgan says investors are “increasingly skittish” ahead of June’s American Society of Clinical Oncology conference, at which Infinity is expected to release safety and tolerability data for its drug. The bank predicts “a good showing” by Infinity but warns it may not be enough to outshine the rivals.
Infinity Pharmaceuticals stock slides
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week